Recent Publications by CFE Educators

Recent Published articles, books, and other scholarship by Academy members, CFE Education Scientists, and CFE Faculty.
Enhanced Myogenesis by Silencing Myostatin with Nonviral Delivery of dCas9 Ribonucleoprotein Complex.
2022
Authors: Chen Y, Banie L, Breyer BN, Tan Y, Wang Z, Zhou F, Wang G, Lin G, Liu J, Qi LS, Lue TF
HIV treatment outcomes in POP-UP: drop-in HIV primary care model for people experiencing homelessness.
2022
Authors: Hickey MD, Imbert E, Appa A, Del Rosario JB, Lynch E, Friend J, Avila R, Clemenzi-Allen A, Riley ED, Gandhi M, Havlir DV
Accuracy and Interrater Reliability of Point-of-Care Ultrasonography Image Interpretation for Intussusception.
2022
Authors: Bergmann KR, Khant M, Lammers S, Arroyo AC, Avendano P, Chaudoin L, Cohen SG, Deanehan JK, Kornblith AE, Lam SHF, Lin-Martore M, Malia L, Pade KH, Park DB, Sivitz A, Shahar-Nissan K, Snelling PJ, Tessaro MO, Thomas-Mohtat R, Whitcomb V, Yock-Corrales A, Walsh P, Watson D, Madhok M, P2Network Intussusception Study Group
Taking the Long Way to Care: Who is Traveling Farthest to Undergo Elective Total Hip Arthroplasty?
2022
Authors: Orringer M, Roberts H, Ward D
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
2022
Authors: Robinson PC, Maksymowych WP, Gensler LS, Hall S, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, de Peyrecave N, Deodhar A
OBJECTIVE
Tumor necrosis factor inhibitors (TNFi) are an effective treatment for non-radiographic axial spondyloarthritis (nr-axSpA). To be eligible, however, many authorities require patients with nr-axSpA to show active sacroiliitis on magnetic resonance imaging (MRI) and/or an elevated C-reactive protein (CRP) level, possibly resulting in a perception that patients with nr-axSpA without both factors have only low responses to TNFi treatment. We evaluated clinical responses to certolizumab pegol (CZP) in patients with nr-axSpA stratified by baseline MRI/CRP status.
METHODS
C-axSpAnd was a phase 3, multicenter study on CZP in adult patients with active nr-axSpA and objective signs of inflammation. This analysis assessed efficacy of CZP over the 52-week randomized, double-blind, placebo-controlled period in patients stratified into subgroups based on the presence of active sacroiliitis on MRI and CRP level at baseline.
RESULTS
CZP-treated patients across all MRI/CRP subgroups achieved clinical responses greater than placebo. Across outcome measures, CZP-treated MRI+/CRP+ patients demonstrated the greatest clinical responses, but substantial improvements were also observed in CZP-treated MRI+/CRP- and MRI-/CRP+ patients. Ankylosing Spondylitis Disease Activity Score Major Improvement response rates at week 52 among CZP-treated patients (75.6% MRI+/CRP+; 47.5% MRI-/CRP+; and 29.7% MRI+/CRP-) were higher than rates in placebo groups (range: 3.9%-12.5%). Assessment of SpondyloArthritis international Society 40% response, Bath Ankylosing Spondylitis Disease Activity Index, and Bath Ankylosing Spondyloarthritis Functional Index had similar response patterns, although differences between the CZP-treated MRI/CRP subgroups were smaller. Clinical responses among CZP-treated patients were also observed in additional subgroups, including those with low Spondyloarthritis Research Consortium of Canada MRI sacroiliac joint inflammation scores and those with normal baseline CRP levels.
CONCLUSION
Our findings indicate that CZP treatment benefits patients with nr-axSpA across MRI+/CRP+, MRI-/CRP+, and MRI+/CRP- subgroups.
View on PubMedRacial Disparities in Endoscopy Cancellations During the COVID-19 Pandemic.
2022
Authors: Wang CW, Mclean I R, Cheng YW, Kim S, Terdiman J, Kathpalia P, Beck KR
An Enhanced Understanding of Culture-Negative Periprosthetic Joint Infection with Next-Generation Sequencing: A Multicenter Study.
2022
Authors: Goswami K, Clarkson S, Phillips CD, Dennis DA, Klatt BA, O'Malley MJ, Smith EL, Gililland JM, Pelt CE, Peters CL, Malkani AL, Palumbo BT, Lyons ST, Bernasek TL, Minter J, Goyal N, McDonald JF, Cross MB, Prieto HA, Lee GC, Hansen EN, Bini SA, Ward DT, Shohat N, Higuera CA, Nam D, Della Valle CJ, Parvizi J, Orthopedic Genomics Workgroup, Orthopedic Genomics Workgroup
The Tea House Series: Striving Together to be Antiracist.
2022
Authors: Shahram Y, Lowry D, Iverson N, Teherani A
BACKGROUND
Though awareness of health care structures that are racist and oppressive is increasing among health care professionals, there is a gap in continuing education curricula focused on antiracist anti-oppressive practices, and limited faculty and staff development to guide individuals towards action.
AIM
To develop, implement, and evaluate a novel antiracist faculty and staff development program called the Tea House Series.
SETTING AND PARTICIPANTS
A five-part continuing education series with an accompanying online community for faculty and staff at the divisions of Hospital Medicine in one institution in the western United States.
PROGRAM DESCRIPTION
The four foundational pillars integral to the Tea House Series were as follows: educational framework based on the pedagogy of Paulo Freire, local disparities data, welcoming space to establish a community of practice and accountability. Each session contained participant dialogue in small group activities.
PROGRAM EVALUATION
Qualitative analysis of participant survey responses demonstrated transformation towards a hope to act with a sense of community. Quantitative analysis measured increased confidence for the program learning objectives.
DISCUSSION
The Tea House Series may be used as a model for continuing education to provide the tools and the community to confront systems of racism and oppression in any institution.
View on PubMedThematic analysis of the psycho-sexual symptoms in patients with Peyronie's disease present on online forums.
2022
Authors: Low P, Wang L, Li KD, Shibley WP, Cedars BE, Holler JT, Enriquez A, Sadeghi-Nejad H, Amend GM, Breyer BN
Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis.
2022
Authors: Abdelhak A, Cordano C, Boscardin WJ, Caverzasi E, Kuhle J, Chan B, Gelfand JM, Yiu HH, Oertel FC, Beaudry-Richard A, Condor Montes S, Oksenberg JR, Lario Lago A, Boxer A, Rojas-Martinez JC, Elahi FM, Chan JR, Green AJ